Unlike most core resource facilities appended to program project grants, the new Validation Core proposed here is more than a detached support unit. The purpose of this core is to assure that the signal obtained from the experiments performed in the major projects is valid, a necessary step before deeper studies, in particular those bound for the clinic, can be undertaken. We will validate the probes and methods produced in several ways, including a) characterization of nanomaterial targeting moieties through use and/or development of suitable binding affinity assays in vitro;b) determination of selective targeting of nanomaterials in cellule through fluorescent or radioactive means;c) ex vivo pharmacokinetic studies in relevant animal models;d) in vivo pharmacokinetic and pharmacodynamic studies through small animal imaging and e) provision of all animalrelated services, including pre-Good Laboratory Practice (GLP) toxicity assays, in collaboration with the Department of Molecular and Comparative Pathobiology (Drs. Gabrielson and Brayton). We will further perform correlation of any imaging studies with traditional ex vivo and histological approaches and will also attempt to cross-correlate, when practical and useful, the MR-based imaging findings with other modalities, especially radionuclide-based and those that employ optical (fluorescence and bioluminescence) imaging. In that regard the validation core will perform a certain degree of its own research - rather than merely providing routine services - but that research will always be related to the major projects. Because validation is critical to any imaging study, the integration of this core to the projects is clear. The goal of this core is to enable the scientists performing the studies of the major projects to focus on the most complex aspects of their work, Interfacing closely with the core not only to procure routine services, but to assure the validity of their results.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA151838-05
Application #
8734341
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
5
Fiscal Year
2014
Total Cost
$127,937
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Song, Xiaolei; Yang, Xing; Ray Banerjee, Sangeeta et al. (2015) Anthranilic acid analogs as diamagnetic CEST MRI contrast agents that feature an intramolecular-bond shifted hydrogen. Contrast Media Mol Imaging 10:74-80
Srivastava, Amit K; Bulte, Jeff W M (2014) Seeing stem cells at work in vivo. Stem Cell Rev 10:127-44
Nimmagadda, Sridhar; Pullambhatla, Mrudula; Lisok, Ala et al. (2014) Imaging Axl expression in pancreatic and prostate cancer xenografts. Biochem Biophys Res Commun 443:635-40
Li, Yang; Foss, Catherine A; Pomper, Martin G et al. (2014) Imaging denatured collagen strands in vivo and ex vivo via photo-triggered hybridization of caged collagen mimetic peptides. J Vis Exp :e51052
Bulte, Jeff W M; Schmieder, Anne H; Keupp, Jochen et al. (2014) MR cholangiography demonstrates unsuspected rapid biliary clearance of nanoparticles in rodents: implications for clinical translation. Nanomedicine 10:1385-8
Bhatnagar, Akrita; Wang, Yuchuan; Mease, Ronnie C et al. (2014) AEG-1 promoter-mediated imaging of prostate cancer. Cancer Res 74:5772-81
Das, Samarjit; Bedja, Djahida; Campbell, Nathaniel et al. (2014) miR-181c regulates the mitochondrial genome, bioenergetics, and propensity for heart failure in vivo. PLoS One 9:e96820
Williford, John-Michael; Wu, Juan; Ren, Yong et al. (2014) Recent advances in nanoparticle-mediated siRNA delivery. Annu Rev Biomed Eng 16:347-70
Shallal, Hassan M; Minn, Il; Banerjee, Sangeeta R et al. (2014) Heterobivalent agents targeting PSMA and integrin-?v?3. Bioconjug Chem 25:393-405
Yang, Xing; Yadav, Nirbhay N; Song, Xiaolei et al. (2014) Tuning phenols with Intra-Molecular bond Shifted HYdrogens (IM-SHY) as diaCEST MRI contrast agents. Chemistry 20:15824-32

Showing the most recent 10 out of 56 publications